Viracta Therapeutics appoints Cohen as CMO

Viracta Therapeutics announced the appointment of Darrel Cohen, M.D., Ph.D. as Chief Medical Officer, CMO, effective immediately. Dr. Cohen will oversee the clinical development and regulatory advancement of Nana-val in Epstein-Barr virus-associated malignances, contribute to the strategic expansion of Viracta’s pipeline, and serve on the Executive Leadership Team. Most recently, Dr. Cohen was CMO of Cell Therapy at Athenex Inc., where he led clinical development, clinical operations, and regulatory affairs for its CAR-NKT cell therapy platform and was instrumental in accelerating clinical development plans for investigational products, KUR-501 and KUR-502.